ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADC Therapeutics posts robust Q4 results, eyes pipeline expansion

ADC Therapeutics delivered strong financial results, bolstered by Zynlonta's sales growth and a healthy cash position.
Strategic decisions on pipeline programs and market access initiatives demonstrate a focus on long-term growth and profitability.
While facing challenges such as market access delays and community adoption hurdles, ADC Therapeutics remains poised for success with multiple growth opportunities ahead.

ADC Therapeutics accelerates pipeline progress and optimizes ZYNLONTA's potential

ADC Therapeutics is making strides in pipeline prioritization and operational efficiencies, focusing on ZYNLONTA's commercial success.
The company faces challenges in navigating market dynamics and implementing strategic changes while capitalizing on growth opportunities.
Opportunities lie in expanding trial sites, exploring potent combinations, and leveraging the new go-to-market model for enhanced performance.
Overall, ADC Therapeutics aims for sustained growth through strategic resource allocation and operational enhancements.

ADC Therapeutics reports revenue growth and strategic expansions in Q2

ADC Therapeutics showcased solid Q2 performance with revenue growth and strategic expansions.
While facing challenges in clinical trials and market dynamics, the company is leveraging strengths in portfolio investments and market positioning.
Opportunities lie in upcoming milestones, international expansions, and innovative sales strategies for sustained growth.

ADC Therapeutics reports mixed Q3 results, positive pipeline outlook

ADC Therapeutics faced challenges in ZYNLONTA sales but showcased positive pipeline updates and promising Cami trial results.
Management's focus on cost control and cash preservation aligns with maintaining financial stability until mid-2025.
Analysts' inquiries into commercial strategies and regulatory timelines reflect market interest and potential growth opportunities.
Overall, ADCT's performance highlights a mix of challenges, strengths, and opportunities in navigating the competitive landscape.

ADC Therapeutics reports robust earnings, eyes expansion in oncology market

ADC Therapeutics demonstrated strong financial performance and progress in clinical trials, positioning itself well for future growth. Strategic focus on key pipelines and real-world data strategies highlight a commitment to innovation.
While facing competition and evolving treatment landscapes, the company has opportunities to expand ZYNLONTA and leverage next-gen platforms. Ongoing partnership discussions and upcoming trial results offer avenues for advancement.
Challenges include market differentiation, safety data focus, and successful trial enrollment. Managing these hurdles while capitalizing on growth opportunities will be crucial for ADC Therapeutics' future success.

ADCT reports revenue growth and strategic advancements in Q1

ADCT's Q1 performance reflects revenue growth, cost management, and strategic investments in pipeline development and financial stability.
Strengths lie in ZYNLONTA's performance, successful fundraising, disciplined capital allocation, and diversified pipeline progress.
Challenges include market competition, net losses, regulatory considerations, and balancing expenses with revenue growth.
Opportunities arise from expanding into new indications, advancing therapeutic candidates, regulatory engagements, and solid tumor pipeline growth.

ADC Therapeutics achieves profitability driven by ZYNLONTA in hematology

ADC Therapeutics demonstrated strong financial performance with commercial profitability and cost management improvements.
The company's focus on hematology and advancements in product pipeline position them for future growth.
While facing challenges in sales variability and market competition, ADC Therapeutics has opportunities for expansion and differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company's Chief Executive Officer in May 2022, will join the Board. “Jean-Pierre is an exceptional addition to our Board,” said Ron Squarer, Chairman of ADC Therapeutics' Board of Directors. “His integral role in the development and approval of leading c

ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. “As ZYNLONTA has been shown in preclinical studies to have synergistic or additive effects when combined with other anti-cancer therapies, we are eager to explore the potential of our differentiated CD19-

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

ADC Therapeutics SA (NYSE: ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response.

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective July 1st. In this role, Mr. Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the Company's executive leadership team. “David Gilman is a seasoned business development and strateg

ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. An overall response rate (ORR) of 70.1% and a complete response (CR) rate of 33.3% was observed with a median duration of response of 13.7 months for all responders in r/r Hodgkin lymphoma patients who were refractory or had relapsed after a median of 6 prior treatments,

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days

ADC Therapeutics to Present at the Jefferies Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022. “We continue to be encouraged by the data from our ongoing pivotal Phase 2 tri

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

ADC Therapeutics SA (NYSE:ADCT ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Chris Martin - Former Chief Executive Officer Jennifer Herron - Chief Commercial Officer Joe Camardo - Chief Medical Officer Jenn Creel - Chief Financial Officer Ameet Mallik - Chief Executive Officer Conference Call Participants Kelly Shi - Jefferies Operator Welcome to the ADC Therapeutics First Quarter 2022 Financial Results Conference Call. My name is Mitchell and I will be your operator for today's call.

ADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q1 2022 Results - Earnings Call Transcript

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the first quarter ended March 31, 2022 and provided business updates. “ZYNLONTA continues to extend its reach in the DLBCL market with its differentiated product profile a

ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. Dr. Martin will serve as a non-executive member of the Company's Board of Directors and Chair of the Science and Technology Com

ADC Therapeutics Announces CEO Transition

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 1:40 pm ET. A live webcast of the presentation will

ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Monday, May 9, 2022 at 8:30 a.m. ET to report financial results for the first quarter 2022 and provide business updates. To access the l

ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that a permanent J-code, J9359, has been issued for ZYNLONTA® by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2022. “As we expand our U.S. ZYNLONTA busi

ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2021, has been filed with the U.S. Securities and Exchange Commission (the “SEC”). ADC Therapeutics' Annual Report on Form

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q4 2021 Results - Earnings Call Transcript

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided business updates. “We are encouraged by the progress of the ZYNLONTA® launch and pleased with its dif

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen's virtual 42nd Annual Health Care Conference on Tuesday, March 8th at 2:10 p.m. EST. A live webc

ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business update

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today unveiled its first Environmental, Social and Governance (ESG) report detailing the Company's focus on patient care and sustainable innovation. The report marks a milestone in the Company's evolution and

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST. “We are excited by our progress to date, having successfully launched ZYNLONTA® for

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST. A live webcast o

ADC Therapeutics to Participate in Guggenheim Oncology Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET. Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan. Under the agreement terms, ADC Therapeutics will receive an upfront payment of $30 million and up to an additional $205 million in milestones payments.

News for ADC Therapeutics Stock (ADCT)